hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06320548, orgStudyIdInfo id: 0724/2018, briefTitle: The Efficacy of Preoperative Low-residue Diet on Postoperative Ileus Following Cesarean Section, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-10-01, primaryCompletionDateStruct date: 2020-11-30, completionDateStruct date: 2020-12-02, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: University of Roma La Sapienza, class: OTHER, descriptionModule briefSummary: The aim of the present study was to evaluate the efficacy of preoperative low-residue diet on postoperative ileus in women undergoing elective cesarean section. It is a surgeon-blind, randomized controlled trial enrolling pregnant women at ≥39 weeks of gestation undergoing elective cesarean section. Patients were preoperatively randomized to receive either low-residue diet (arm A) or free diet (arm B) starting from three days before surgery. The primary outcome was the postoperative ileus at 24 hours after surgery. The secondary outcomes were the postoperative pain (assessed through VAS scale), the quality of the surgical field (scored using a 5-point scale, from poor to excellent), postoperative complications, and the length of hospital stay. Perioperative data were collected and compared between groups., conditionsModule conditions: Cesarean Section Complications, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 166, type: ACTUAL, armsInterventionsModule interventions name: Low-residue diet, interventions name: Free diet, outcomesModule primaryOutcomes measure: Number of participants who have passage of flatus within the first 24 hours after caesarean section., secondaryOutcomes measure: Postoperative pain, secondaryOutcomes measure: Postoperative complications, secondaryOutcomes measure: Quality of the surgical field, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sapienza University of Rome, city: Rome, country: Italy, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06320535, orgStudyIdInfo id: VAC096, briefTitle: A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: University of Oxford, class: OTHER, collaborators name: Bill and Melinda Gates Foundation, collaborators name: University Hospitals Bristol and Weston NHS Foundation Trust, descriptionModule briefSummary: This is a phase I clinical study that aims to assess the safety and immunogenicity of a novel, escalating dose regimen of R21/Matrix-M™ in healthy, malaria-naïve adults., conditionsModule conditions: Malaria,Falciparum, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: R21/Matrix M™ (Group 1), interventions name: R21/Matrix M™ (Group 2), interventions name: R21/Matrix M™ (Group 3), interventions name: Fine needle aspiration (FNA), outcomesModule primaryOutcomes measure: To compare the safety of R21/Matrix-M™ administered in an escalating dose, multi prime vaccination schedule with a standard prime-boost regimen in healthy UK adults, primaryOutcomes measure: To compare the safety of R21/Matrix-M™ administered in an escalating dose, multi prime vaccination schedule with a standard prime-boost regimen in healthy UK adults, primaryOutcomes measure: To compare the humoral immunogenicity of R21/Matrix-M™ administered in an escalating dose, multi-prime vaccination schedule with a standard prime-boost regimen in healthy UK adults, otherOutcomes measure: To assess the relationship between vaccination schedule and humoral immune response in participants vaccinated with R21/Matrix-M™ administered in escalating dose, multi-prime vaccination schedules compared with a standard prime-boost regimen, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Centre for Clinical Vaccinology and Tropical Meducine, Churchill Hospital, University of Oxford, status: RECRUITING, city: Oxford, state: Oxfordshire, zip: OX3 7LE, country: United Kingdom, contacts name: Volunteer Recruitment Co-ordinator, role: CONTACT, phone: 01865611386, email: vaccinetrials@ndm.ox.ac.uk, geoPoint lat: 51.75222, lon: -1.25596, locations facility: University Hospitals Bristol and Weston NHS Foundation Trust, status: NOT_YET_RECRUITING, city: Bristol, zip: BS2 8HW, country: United Kingdom, contacts name: Rajeka Lazarus, DPhil FCRPath, role: CONTACT, email: rajeka.lazarus@uhbristol.nhs.uk, contacts name: Rajeka Lazarus, DPhil FRCPath, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 51.45523, lon: -2.59665, hasResults: False
protocolSection identificationModule nctId: NCT06320470, orgStudyIdInfo id: HUM00231159a, secondaryIdInfos id: VMR2022-03, type: OTHER_GRANT, domain: Michigan, State of, Licensing and Regulatory Affairs, Department of 573000, briefTitle: MIVetsCan: Can-Coach Trial (Phase 1), statusModule overallStatus: COMPLETED, startDateStruct date: 2023-08-07, primaryCompletionDateStruct date: 2023-12-11, completionDateStruct date: 2023-12-11, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: University of Michigan, class: OTHER, collaborators name: Michigan, State of, Licensing and Regulatory Affairs, descriptionModule briefSummary: The goal of the MIVetsCan Can-Coach Trial is to pilot and modify a trial of four coaching sessions to help Veterans with chronic pain use their own cannabis products more effectively to manage pain and related symptoms., conditionsModule conditions: Chronic Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 22, type: ACTUAL, armsInterventionsModule interventions name: Educational Session, outcomesModule primaryOutcomes measure: Patient Global Impression of Change (PGIC) score, secondaryOutcomes measure: Average satisfaction level of the cannabis coaching overall assessed from a single survey question on satisfaction., secondaryOutcomes measure: Average helpfulness level of the cannabis coaching assessed from a single survey question on cannabis coaching., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The University of Michigan, city: Ann Arbor, state: Michigan, zip: 48109, country: United States, geoPoint lat: 42.27756, lon: -83.74088, hasResults: False
protocolSection identificationModule nctId: NCT06320444, orgStudyIdInfo id: CRFSJ0297, briefTitle: Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-15, primaryCompletionDateStruct date: 2024-12-15, completionDateStruct date: 2025-07-15, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: University of Dublin, Trinity College, class: OTHER, collaborators name: Motor Neurone Disease Association, UK, collaborators name: Irish Research Council, IE, collaborators name: Health Research Board, IE, collaborators name: Research Motor Neurone, IE, collaborators name: Thierry Latran Foundation, FR, collaborators name: ALS Association, USA, descriptionModule briefSummary: Substantial variability exists in the onset, and rate of degeneration across individuals with Motor Neurone Disease (MND) or Amyotrophic Lateral Sclerosis (ALS). This variability requires biomarkers that accurately classify and reliably track clinical subtypes as the disease progresses. Degeneration occurs in the brain and spinal cord, however, non-invasive diagnosis of spinal cord function remains highly challenging due to its unique alignment in spine. Disruption of complex spinal and cortical circuits that transmit and process neural signals for position sense and movement has not been adequately captured in the neurophysiological profiling of ALS patients. The overarching aim of this study is to reveal and quantify the extent of change in the sensorimotor integration and its potential contribution to network disruption in ALS., conditionsModule conditions: Motor Neuron Disease, Amyotrophic Lateral Sclerosis, conditions: Motor Neuron Disease Progressive Spinal Muscle Atrophy, conditions: Primary Lateral Sclerosis, conditions: Multiple Sclerosis, conditions: Postpoliomyelitis Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG), outcomesModule primaryOutcomes measure: Biomarker of sensorimotor integration, primaryOutcomes measure: Determination of the feasibility of sensorimotor signatures as reliable biomarkers of ALS, primaryOutcomes measure: Non-invasive recording of the SC functional neuro-electric activity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Academic Unit of Neurology, Trinity College Dublin, The University of Dublin, status: RECRUITING, city: Dublin, state: Leinster, zip: Dublin 2, country: Ireland, contacts name: Orla Hardiman,, BSc MB BCh BAO MD FRCPI FAAN, role: CONTACT, phone: +353 1 896 4497, email: hardimao@tcd.ie, contacts name: Prabhav Mehra, BE MSc, role: CONTACT, phone: +3530894781347‬, email: mehrap@tcd.ie, geoPoint lat: 53.33306, lon: -6.24889, hasResults: False
protocolSection identificationModule nctId: NCT06320418, orgStudyIdInfo id: RHDIRB2020110301REC#196, briefTitle: The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-06-15, primaryCompletionDateStruct date: 2023-12-10, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: Ovarian cancer (OC) has one of the highest mortality rates for female malignant tumors, attributed to advanced cancer stages upon diagnosis as well as a high recurrence rate. Piwi-interacting RNA-823 (piR-823) is a single-stranded non-protein coding RNA (ncRNA) star molecule in epigenetics research. Extensive cellular regulatory functions and aberrant expression of piR-823 have been implicated in carcinogenesis. Therefore, the findings of piwi-ncRNA dysregulated-expression in OC Egyptian female patients' cohort could be employed as a potential novel mechanism for OC precision, a step toward ncRNA-precision, conditionsModule conditions: Ovarian Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 56, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Association of piR-823 expression with ovarian cancer progression, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab, city: Cairo, zip: 11566, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06320392, orgStudyIdInfo id: RHDIRB2020110301 REC#48, briefTitle: Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer, acronym: CCR4-NOT, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2021-07-01, primaryCompletionDateStruct date: 2023-05-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: Being a mechanistic study, this work aims to figure out "the role of the cytoplasmic mRNA deadenylase CNOT7 expressed protein on NK cell resistance in metastatic BC". In other words, to explore, whether, "CNOT7 contributes to metastasis in Egyptian female metastatic BC patient's cohort, through NK cell resistance, or not.", conditionsModule conditions: Metastatic Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 90, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Cytoplasmic mRNA deadenylase CNOT7 protein expression level in metastatic/advanced localized and non-metastatic BC sera using ELISA., primaryOutcomes measure: CNOT7 tissue expression level in BC tissue samples categorized as metastatic vs non-metastatic tumor alongside with adjacent non-tumor tissue margin using immunohistochemistry., primaryOutcomes measure: LAIR-1 protein expression level in BC patients peripheral blood samples using ELISA., eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab, city: Cairo, zip: 11566, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06320366, orgStudyIdInfo id: 23-1044, secondaryIdInfos id: K24DA058882, type: NIH, link: https://reporter.nih.gov/quickSearch/K24DA058882, briefTitle: Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2028-05-31, completionDateStruct date: 2028-05-31, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: University of Colorado, Denver, class: OTHER, collaborators name: National Institute on Drug Abuse (NIDA), descriptionModule briefSummary: The investigators will evaluate the effects of an accelerated Transcranial Magnetic Stimulation (TMS) protocol of the left dorsolateral prefrontal cortex (DLPFC) for moderate to severe methamphetamine use disorder. This is a randomized parallel group design to assess feasibility and safety, evaluate efficacy (use, craving) and identify magnetic resonance imaging (resting state and cue craving) associated with group/outcomes., conditionsModule conditions: Methamphetamine Use Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Sham vs. real Transcranial Magnetic Stimulation (TMS), primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: Participant and all study personnel are blinded., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Sham TMS, interventions name: Active TMS, outcomesModule primaryOutcomes measure: Tolerability, primaryOutcomes measure: Study emergent adverse events, secondaryOutcomes measure: Weeks of continuous abstinence, secondaryOutcomes measure: Days of methamphetamine use, secondaryOutcomes measure: Methamphetamine craving, secondaryOutcomes measure: Methamphetamine craving on visual analog scale, secondaryOutcomes measure: MRI cue craving, secondaryOutcomes measure: MRI resting state, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Colorado Anschutz Medical Campus, city: Aurora, state: Colorado, zip: 80045, country: United States, contacts name: Joseph T Sakai, MD, role: CONTACT, phone: 303-724-7402, email: joseph.sakai@cuanschutz.edu, contacts name: Kristen M Raymond, BA, role: CONTACT, phone: 303-724-3196, email: kristen.raymond@cuanschutz.edu, contacts name: Joseph T Sakai, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.72943, lon: -104.83192, hasResults: False
protocolSection identificationModule nctId: NCT06320340, orgStudyIdInfo id: 07032024, briefTitle: Effectiveness of NMES on Neck Pain, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-03-15, primaryCompletionDateStruct date: 2021-05-15, completionDateStruct date: 2021-09-15, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Istanbul University - Cerrahpasa (IUC), class: OTHER, descriptionModule briefSummary: The aim of this randomized-controlled study was to determine the effectiveness of neuromuscular electrical stimulation (NMES) applied simultaneously to exercise on pain, static endurance of cervical deep flexor muscles, fear of movement and disability in chronic neck pain. The participants were randomly assigned to one group which in only five clinical pilates exercises were performed (Group I) or the other group which NMES was applied on lower trapezius and serratus anterior muscles while the same exercises were performing (Group II)., conditionsModule conditions: Chronic Neck Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 36, type: ACTUAL, armsInterventionsModule interventions name: Exercise, interventions name: Electrotherapy, outcomesModule primaryOutcomes measure: Neck disability, primaryOutcomes measure: Neck disability, secondaryOutcomes measure: Pain intensity, secondaryOutcomes measure: Pain intensity, secondaryOutcomes measure: Range of Motion, secondaryOutcomes measure: Range of Motion, secondaryOutcomes measure: Static endurance of cervical deep flexor muscles, secondaryOutcomes measure: Static endurance of cervical deep flexor muscles, secondaryOutcomes measure: Fear of the movement, secondaryOutcomes measure: Fear of the movement, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: İstanbul Aydın University, city: İstanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06320314, orgStudyIdInfo id: LRP23021-E serum, briefTitle: Efficacy and Tolerability of Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2024-05-22, completionDateStruct date: 2024-05-22, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Cosmetique Active International, class: INDUSTRY, descriptionModule briefSummary: The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo., conditionsModule conditions: Hyperpigmentation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: tested product (2039125 03), outcomesModule primaryOutcomes measure: IGA score for patients with melasma or acne induced post-inflammatory hyperpigmentation (PIHP), primaryOutcomes measure: modified Melasma Area and Severity Index (mMASI) for patients with melasma, primaryOutcomes measure: Post-Acne Hyperpigmentation Index (PAHPI), secondaryOutcomes measure: colorimetry measurements, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: PhDTrials Center, status: RECRUITING, city: Lisboa, country: Portugal, contacts name: Pedro Pinto, role: CONTACT, phone: +351 216034267, phoneExt: 501, email: geral@phdtrials.com, geoPoint lat: 38.71667, lon: -9.13333, hasResults: False
protocolSection identificationModule nctId: NCT06320301, orgStudyIdInfo id: SYSKY-2024-027-01, briefTitle: Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-02-01, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, class: OTHER, collaborators name: Suzhou Suncadia Biopharmaceuticals Co., Ltd., descriptionModule briefSummary: Patients with advanced biliary tract malignant tumors who had not received systematic treatment before and could not be cured were selected as the subjects of the study. The primary endpoint of the study was investigator-assessed 6-month progression-free survival (6-month PFS%) based on the RECIST v1.1 criteria, and 43 subjects were planned to be enrolled. Patients eligible for enrollment will receive Adebrelimab and a tyrosine kinase inhibitor (TKI) in combination with gemcitabine and oxaliplatin (GEMOX)., conditionsModule conditions: Biliary Tract Cancer, conditions: Gemox Chemotherapy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 43, type: ESTIMATED, armsInterventionsModule interventions name: Adebrelimab + GEMOX + TKI, outcomesModule primaryOutcomes measure: the effectiveness of first-line treatment with Adebrelimab and a tyrosine kinase inhibitor (TKI) in combination with gemcitabine and oxaliplatin (GEMOX) in patients with advanced BTC, secondaryOutcomes measure: To assess the progression-free survival (PFS), secondaryOutcomes measure: To evaluate the time to progression (TTP), secondaryOutcomes measure: To evaluate the disease control rate (DCR),, secondaryOutcomes measure: To evaluate the objective response rate (ORR), secondaryOutcomes measure: To evaluate the duration of response (DoR), secondaryOutcomes measure: To evaluate the overall survival (OS)., otherOutcomes measure: To explore the correlation between biomarkers and the efficacy of the combination regimen., otherOutcomes measure: The PFS based on an immunomodified RECIST (imRECIST）, otherOutcomes measure: The TTP based on an immunomodified RECIST (imRECIST）, otherOutcomes measure: The ORR based on an immunomodified RECIST (imRECIST）, otherOutcomes measure: The DCR based on an immunomodified RECIST (imRECIST）, otherOutcomes measure: The DoR based on an immunomodified RECIST (imRECIST）, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University, status: RECRUITING, city: Guanzhou, state: Guangdong, zip: 512000, country: China, contacts name: Junkai Ren, role: CONTACT, phone: 86-18664506517, email: rjk119234@163.com, contacts name: Wenbin Li, role: CONTACT, phone: 86-13602773101, hasResults: False